About Stipple Bio
Stipple Bio is a private company based in Cambridge, Massachusetts, incorporated in 2021 in Delaware. It has reported $86,581,083 raised in three offerings on Form D since June 2022. Its chief executive is Jeffrey Landau.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Apr 6, 2026 | $65,130,013of $100.2M target | 15 | $4.3M | EquityRule 506(b) | Form D ↗ |
| Dec 20, 2024 | Dec 20, 2024 | $9,476,070of $15.0M target | 1 | $9.4M | EquityRule 506(b) | Form D ↗ |
| May 31, 2022 | Jun 7, 2022 | $11,975,000of $12.0M target | 7 | $1.7M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $86,581,083 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Stipple Bio's Form D filed Apr 6, 2026.
Vineeta Agarwala
Director
Also a director at Arda Therapeutics, BigHat Biosciences and Rezo Therapeutics.
GV
Greg Verdine
Independent Director
TS
OH
Owen Hughes
Independent Director
AR
Aaron Ring
Associate Professor, Fred Hutch and director
Also an executive officer and director at Seranova Bio.
DD
Derek DiRocco
Partner, RA Capital Management and director
Earlier filings also listed Antoine Yver (director, last listed Dec 2024).